As The Scientist reported on Friday, the ORI found that Mona Thiruchelvam faked cell counts in two grant applications and a number of papers that claimed to show how the pesticides paraquat, maneb, and atrazine might affect parts of the brain involved in Parkinson’s. The Scientist notes: Continue reading ORI finds Parkinson’s-pesticides researcher guilty of faking data; two papers to be retracted
Peter Francis, a former Oregon Health Sciences University (OHSU) eye researcher, has been sanctioned by the U.S. Office of Research Integrity (ORI) for claiming, in grant applications, to have performed experiments that he hadn’t actually done.
In two unrelated cases, the Office of Research Integrity (ORI) has sanctioned a grad student and a pair of colleagues, one of whom plagiarized and the other allowed the intellectual theft to go unchecked.
We think the handling of these cases — both first noted briefly by The Chronicle of Higher Education — is worth noting.
In the wake of the massive allegations of fraud by resveratrol researcher Dipak Das, other researchers in the field are clearly trying to distance themselves from the University of Connecticut scientist. Nir Barzilai told us yesterday, for example, that despite Das seemingly’ impressive publication record, “Rome was not built on Dr. Das.”
Harvard’s David Sinclair went further, telling The New York Times that he didn’t know who Das was: Continue reading So how peripheral was Dipak Das’ resveratrol work, really?
Many Retraction Watch readers will now be familiar with the case of Dipak Das, the resveratrol researcher about whom the University of Connecticut issued a voluminous report yesterday — summary here — detailing 145 counts of data fabrication and falsification. This has been a fast-moving story, so we wanted to highlight a number of updates to our original post, and offer a few more.
First, we have confirmed with publisher Mary Ann Liebert this morning that Das has been relieved of his duties as co-editor in chief of Antioxidants & Redox Signaling. He had shared that post with Chandan Sen, and his name as been removed from the masthead of that journal. Here’s a statement from the publisher: Continue reading Resveratrol fraud case update: Dipak Das loses editor’s chair, lawyer issues statement refuting all charges
The Office of Research Integrity has thrown a heavy book at Bengu Sezen, a former chemist at Columbia University, alleging that school and agency investigators turned up 21 instances of research misconduct by the disgraced scientist.
Take the case of Hung-Shu Chang. Last week, the the federal Office of Research Integrity announced that it had closed its investigation into the scientist’s misdeeds. Chang was a visiting postdoctoral researcher from Taiwan who in 2005 had come to the renowned Skinner Laboratory at Washington State University to study the effects of endocrine disruptors — a class of compounds that includes BPA and which have been shown to disrupt the action of hormones — on sex cells.
Chang was accused of falsifying data in a 2006 paper in Endocrinology — later retracted — reporting the damaging effects of vinclozolin, a fungicide used to protect vineyards, on the genetic integrity of sperm cells.
According to federal and university investigators, Chang, who has since returned to Taiwan, “fabricated and falsified data” central to the authors’ claim that vinclozolin could alter sperm in such a way that the mutations could cause disease in future generations. Such mutations are referred to as epigenetic changes. Continue reading What happens after a retraction for falsified data? An example from Endocrinology